[1] Seo YS, Park SY, Kim MY,et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage[J].Hepatology,2014, 60(3):954-961.
[2] 阿英, 陈文光. 醋酸奥曲肽对肝硬化合并上消化道出血患者治疗的疗效观察[J].国际消化病杂志, 2016, 36(4):249-251.
[3] Liu S. Management of upper gastrointestinal bleeding from portal hypertension: Elective or emergency operation[J].Pak J Med Sci,2014, 30(3):574-577.
[4] 何毅, 董卫国. 奥曲肽联合普萘洛尔治疗肝硬化上消化道出血疗效的meta分析[J].职业与健康, 2015, 31(3):332-335.
[5] Kalambokis GN, Christodoulou D, Baltayiannis G, et al. Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites[J].Hepatology,2016, 64(5):1806-1811.
[6] Gupta V, Rawat R, Shalimar, et al. Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT[J].Hepatol Int,2017,18(41):1-7.
[7] 史长山, 孔百春, 王晓光. 奥曲肽联合普萘洛尔治疗肝硬化上消化道出血及其对血流动力学的影响[J].检验医学, 2016,19(11):296-297.
[8] Kong DR, Wang JG, Sun B, et al. β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis[J].World J Gastroenterol,2015, 21(23):7191-7196.
[9] Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
[J].Hepatology,2015, 62(2):567-574.
[10] 贺永锋, 杨小翠, 张健涛,等. 奥曲肽联合普萘洛尔治疗肝硬化食管胃底静脉曲张破裂后出血的临床分析[J].药物评价研究, 2016, 39(2):274-277.
[11] 王永栋, 刘建茹, 王莹,等. 奥曲肽和普萘洛尔治疗肝硬化上消化道出血对疗效及血流动力学的影响[J].河北医药, 2016,11(5):706-708. |
2018, Vol. 35 
